{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:30:54Z","timestamp":1779201054587,"version":"3.51.4"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,17]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The standard of care for locoregionally advanced nasopharyngeal carcinoma (LA-NPC) is induction chemotherapy (ICT) followed by concurrent chemoradiation (CCRT). However, the ideal ICT regimen for LA-NPC remains unclear. We conducted a meta-analysis to evaluate the survival outcomes, responses, and incidences of toxicities between taxane, cisplatin and fluorouracil (TPF) and cisplatin and fluorouracil (PF) ICT regimens plus CCRT in LA-NPC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic review and meta-analysis of the literature was conducted to compare the efficacy and safety of TPF versus PF followed by CCRT with cisplatin every 3 weeks or weekly cisplatin and intensity-modulated radiotherapy in LA-NPC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Three studies with 2482 patients met the inclusion criteria. ICT with the TPF regimen plus CCRT resulted in a significantly improved progression-free survival (hazard ratios [HR] 0.84 [95% CI 0.73\u20130.96], <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.01), overall survival (HR 0.83 [95% CI 0.71\u20130.97], <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.02), and 3-year locoregional recurrence-free survival (risk ratios [RR] 1.03 [95% CI 1.01\u20131.06], <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.009) compared with the PF regimen plus CCRT in LA-NPC. However, distant metastasis-free survival was not statistically significant (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.07). The incidence of grade 3 or 4 neutropenia (RR 2.08 [95% CI 1.84\u20132.36]) and diarrhea (RR 1.94 [95% CI 1.07\u20133.52]) during ICT was higher in the TPF group than in the PF group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In terms of progression-free survival, overall survival, locoregional recurrence-free survival, in the era of intensity-modulated radiotherapy, the TPF plus CCRT with cisplatin is superior to PF plus CCRT with cisplatin in LA-NPC. Thus, the TPF plus CCRT regimen appears to be a reasonable treatment option, and further confirmation by prospective studies is needed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000041278","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T03:01:45Z","timestamp":1737428505000},"page":"e41278","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of TPF and PF induction chemotherapy combined with cisplatin concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2378-8702","authenticated-orcid":false,"given":"Haiwen","family":"Li","sequence":"first","affiliation":[{"name":"Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China"},{"name":"Department of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qibiao","family":"Wu","sequence":"additional","affiliation":[{"name":"Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China"},{"name":"The State Key Laboratory for Quality Research in Chinese Medicines of the Macau University of Science and Technology, Macau, P.R. China"},{"name":"Guangdong-Hong Kong-Macao Joint Laboratory for Contaminants Exposure and Health, Guangdong University of Technology, Guangzhou, Guangdong, P.R. China"},{"name":"Zhuhai MUST Science and Technology Research Institute, Zhuhai, Guangdong, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiqing","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Clinical Research Service Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenmei","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Yu","sequence":"additional","affiliation":[{"name":"Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China"},{"name":"The State Key Laboratory for Quality Research in Chinese Medicines of the Macau University of Science and Technology, Macau, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250121","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250121","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","article-title":"Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up(dagger).","volume":"32","author":"Bossi","year":"2021","journal-title":"Ann Oncol"},{"key":"R3-20250121","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.20.03237","article-title":"Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline.","volume":"39","author":"Chen","year":"2021","journal-title":"J Clin Oncol"},{"key":"R4-20250121","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40880-016-0167-2","article-title":"Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy.","volume":"35","author":"Mao","year":"2016","journal-title":"Chin J Cancer"},{"key":"R5-20250121","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.radonc.2020.10.005","article-title":"Combining tumor response and personalized risk assessment: Potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.","volume":"155","author":"Luo","year":"2021","journal-title":"Radiother Oncol"},{"key":"R6-20250121","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2017.01.002","article-title":"Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial.","volume":"75","author":"Chen","year":"2017","journal-title":"Eur J Cancer"},{"key":"R7-20250121","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.18632\/aging.204246","article-title":"Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.","volume":"14","author":"Mu","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"R8-20250121","doi-asserted-by":"crossref","first-page":"619625","DOI":"10.3389\/fonc.2020.619625","article-title":"The clinical outcomes and toxicities of induction chemotherapy followed by concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma.","volume":"10","author":"Zou","year":"2020","journal-title":"Front Oncol"},{"key":"R9-20250121","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2017.07.020","article-title":"Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a prospective, multi-center, randomized clinical trial.","volume":"126","author":"Yang","year":"2018","journal-title":"Radiother Oncol"},{"key":"R10-20250121","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ijrobp.2019.03.043","article-title":"Locoregional control and mild late toxicity after reducing target volumes and radiation doses in patients with locoregionally advanced nasopharyngeal carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study.","volume":"104","author":"Zhao","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R11-20250121","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4143\/crt.2018.250","article-title":"Reduction of target volume and the corresponding dose for the tumor regression field after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.","volume":"51","author":"Wang","year":"2019","journal-title":"Cancer Res Treat"},{"key":"R12-20250121","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","article-title":"Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma.","volume":"27","author":"Hui","year":"2009","journal-title":"J Clin Oncol"},{"key":"R13-20250121","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ijrobp.2015.01.002","article-title":"Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2\/3 trial in locally advanced nasopharyngeal carcinoma.","volume":"91","author":"Tan","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R14-20250121","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"R15-20250121","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2016.12.039","article-title":"Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial.","volume":"75","author":"Cao","year":"2017","journal-title":"Eur J Cancer"},{"key":"R16-20250121","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma.","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"key":"R17-20250121","doi-asserted-by":"crossref","first-page":"927510","DOI":"10.3389\/fonc.2022.927510","article-title":"Induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis.","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"R18-20250121","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1007\/s00405-022-07435-2","article-title":"Optimal induction chemotherapy regimen for locoregionally advanced nasopharyngeal carcinoma: an update Bayesian network meta-analysis.","volume":"279","author":"Wu","year":"2022","journal-title":"Eur Arch Oto-Rhino Laryngol"},{"key":"R19-20250121","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hed.26932","article-title":"The best choice of induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma: Bayesian network meta-analysis.","volume":"44","author":"Liu","year":"2022","journal-title":"Head Neck"},{"key":"R20-20250121","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(21)00075-9","article-title":"Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.","volume":"22","author":"Lv","year":"2021","journal-title":"Lancet Oncol"},{"key":"R21-20250121","doi-asserted-by":"crossref","first-page":"101625","DOI":"10.1016\/j.eclinm.2022.101625","article-title":"Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial.","volume":"53","author":"Wang","year":"2022","journal-title":"EClinicalMedicine"},{"key":"R22-20250121","first-page":"2064","article-title":"Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase II clinical trial.","volume":"6","author":"Tang","year":"2016","journal-title":"Am J Cancer Res"},{"key":"R23-20250121","doi-asserted-by":"crossref","first-page":"626145","DOI":"10.3389\/fonc.2021.626145","article-title":"The most efficacious induction chemotherapy regimen for locoregionally advanced nasopharyngeal carcinoma: a network meta-analysis.","volume":"11","author":"Choi","year":"2021","journal-title":"Front Oncol"},{"key":"R24-20250121","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.tranon.2019.01.002","article-title":"Cisplatin and fluorouracil induction chemotherapy with or without docetaxel in locoregionally advanced nasopharyngeal carcinoma.","volume":"12","author":"Jin","year":"2019","journal-title":"Transl Oncol"},{"key":"R25-20250121","first-page":"1018","article-title":"Clinical observation of TPF induction chemotherapy versus PF induction chemotherapy combined with concurrent chemoradiotherapy for the treatment of locoregionally advanced nasopharyngeal.","volume":"26","author":"Ma","year":"2016","journal-title":"China Oncology"},{"key":"R26-20250121","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jamaoncol.2022.0122","article-title":"Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, And Capecitabine Vs Cisplatin And Fluorouracil On Failure-Free Survival For Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: a multicenter phase 3 Randomized Clinical Trial.","volume":"8","author":"Li","year":"2022","journal-title":"JAMA Oncol"},{"key":"R27-20250121","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R28-20250121","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R29-20250121","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R30-20250121","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"15, Suppl","key":"R31-20250121","first-page":"6032","article-title":"A phase III multicenter randomized clinical trial to compare cisplatin plus fluorouracil with or without docetaxel as the first-line induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: longterm outcomes update. Trial registry record; Clinical trial protocol.","volume":"39","author":"Zheng","year":"2021","journal-title":"J Clin Oncol"},{"key":"R32-20250121","first-page":"14209","article-title":"Interim analysis of a prospective randomized non-inferiority trial of cisplatin and fluorouracil induction chemotherapy with or without docetaxel in nasopharyngeal carcinoma.","volume":"6","author":"Jin","year":"2016","journal-title":"Oncotarget"},{"key":"R33-20250121","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.oraloncology.2018.02.011","article-title":"Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: a big-data intelligence platform-based analysis.","volume":"79","author":"Peng","year":"2018","journal-title":"Oral Oncol"},{"key":"R34-20250121","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma.","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"R35-20250121","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.22.00327","article-title":"Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III Trial.","volume":"40","author":"Zhang","year":"2022","journal-title":"J Clin Oncol"},{"key":"R36-20250121","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/annonc\/mdx770","article-title":"A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02).","volume":"29","author":"Frikha","year":"2018","journal-title":"Ann Oncol"},{"key":"R37-20250121","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.","volume":"119","author":"Yang","year":"2019","journal-title":"Eur J Cancer"},{"key":"R38-20250121","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1002\/hed.26699","article-title":"Assessment of different induction chemotherapy regimens in locally advanced nasopharyngeal carcinoma: meta-analysis.","volume":"43","author":"Guan","year":"2021","journal-title":"Head Neck"},{"key":"R39-20250121","doi-asserted-by":"crossref","first-page":"104","DOI":"10.21037\/atm.2019.02.15","article-title":"Which induction chemotherapy regimen followed by cisplatin-based concurrent chemoradiotherapy is the best choice among PF, TP and TPF for locoregionally advanced nasopharyngeal carcinoma?","volume":"7","author":"He","year":"2019","journal-title":"Ann Translat Med"},{"key":"R40-20250121","doi-asserted-by":"crossref","first-page":"103244","DOI":"10.1016\/j.critrevonc.2021.103244","article-title":"Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: AN updated network meta-analysis.","volume":"160","author":"Bongiovanni","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"R41-20250121","doi-asserted-by":"crossref","first-page":"105555","DOI":"10.1016\/j.oraloncology.2021.105555","article-title":"Nomogram-aided individual induction chemotherapy regimen selection in advanced nasopharyngeal carcinoma.","volume":"122","author":"Peng","year":"2021","journal-title":"Oral Oncol"},{"key":"R42-20250121","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00280-015-2933-2","article-title":"International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents.","volume":"77","author":"Casanova","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"R43-20250121","doi-asserted-by":"crossref","first-page":"765378","DOI":"10.3389\/fonc.2021.765378","article-title":"Efficacy and toxicity of three induction chemotherapy regimens in locoregionally advanced nasopharyngeal carcinoma: outcomes of 10-Year Follow-Up.","volume":"11","author":"Peng","year":"2021","journal-title":"Front Oncol"},{"key":"R44-20250121","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0140-6736(18)31071-7","article-title":"Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.","volume":"38","author":"Liu","year":"2018","journal-title":"Cancer Commun (London, England)"},{"key":"R45-20250121","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1007\/s00520-015-2686-9","article-title":"The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.","volume":"23","author":"Wang","year":"2015","journal-title":"Support Care Cancer"},{"key":"R46-20250121","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"key":"R47-20250121","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.radonc.2011.12.022","article-title":"Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.","volume":"104","author":"Loong","year":"2012","journal-title":"Radiother Oncol"},{"key":"R48-20250121","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/cas.13474","article-title":"Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy.","volume":"109","author":"Lv","year":"2018","journal-title":"Cancer Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T03:02:05Z","timestamp":1737428525000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041278","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]}}}